Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells

Shingo Kozono, Kenoki Ohuchida, Daiki Eguchi, Naoki Ikenaga, Kenji Fujiwara, Lin Cui, Kazuhiro Mizumoto, Masao Tanaka

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Pancreatic stellate cells (PSC), which are implicated in desmoplasia in pancreatic cancer, enhance the malignancy of cancer cells and confer resistance to established treatments. We investigated whether the antifibrotic agent pirfenidone can suppress desmoplasia and exert antitumor effects against pancreatic cancer. Primary PSCs were established from pancreatic cancer tissue obtained during surgery. In vitro, pirfenidone inhibited the proliferation, invasiveness, and migration of PSCs in a dose-dependent manner. Although supernatants of untreated PSCs increased the proliferation, invasiveness, and migration of pancreatic cancer cells (PCC), supernatants of pirfenidone-treated PSCs decreased these effects. Exposure to PCC supernatant increased the production of platelet-derived growth factor-A, hepatic growth factor, collagen type I, fibronectin, and periostin in PSCs, which was significantly reduced by pirfenidone. Mice were subcutaneously implanted with PCCs (SUIT-2 cells) and PSCs into the right flank and PCCs alone into the left flank. Oral administration of pirfenidone to these mice significantly reduced tumor growth of co-implanted PCCs and PSCs, but not of PCCs alone. Pirfenidone also decreased the proliferation of PSCs and the deposition of collagen type I and periostin in tumors. In mice with orthotopic tumors consisting of PCCs co-implanted with PSCs, pirfenidone suppressed tumor growth, reduced the number of peritoneal disseminated nodules, and reduced the incidence of liver metastasis. Pirfenidone in combination with gemcitabine more effectively suppressed orthotopic tumor growth compared with pirfenidone or gemcitabine alone. In conclusion, our findings indicate that pirfenidone is a promising antitumor agent for pancreatic cancer, owing to its suppression of desmoplasia through regulating PSCs.

Original languageEnglish
Pages (from-to)2345-2356
Number of pages12
JournalCancer Research
Volume73
Issue number7
DOIs
Publication statusPublished - Apr 1 2013

Fingerprint

Pancreatic Neoplasms
gemcitabine
Neoplasms
Collagen Type I
Pancreatic Stellate Cells
Growth
pirfenidone
Liver
Fibronectins
Antineoplastic Agents
Oral Administration
Intercellular Signaling Peptides and Proteins
Neoplasm Metastasis
Incidence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. / Kozono, Shingo; Ohuchida, Kenoki; Eguchi, Daiki; Ikenaga, Naoki; Fujiwara, Kenji; Cui, Lin; Mizumoto, Kazuhiro; Tanaka, Masao.

In: Cancer Research, Vol. 73, No. 7, 01.04.2013, p. 2345-2356.

Research output: Contribution to journalArticle

Kozono, Shingo ; Ohuchida, Kenoki ; Eguchi, Daiki ; Ikenaga, Naoki ; Fujiwara, Kenji ; Cui, Lin ; Mizumoto, Kazuhiro ; Tanaka, Masao. / Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. In: Cancer Research. 2013 ; Vol. 73, No. 7. pp. 2345-2356.
@article{442d5bdd28aa48a881f624a10bba5450,
title = "Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells",
abstract = "Pancreatic stellate cells (PSC), which are implicated in desmoplasia in pancreatic cancer, enhance the malignancy of cancer cells and confer resistance to established treatments. We investigated whether the antifibrotic agent pirfenidone can suppress desmoplasia and exert antitumor effects against pancreatic cancer. Primary PSCs were established from pancreatic cancer tissue obtained during surgery. In vitro, pirfenidone inhibited the proliferation, invasiveness, and migration of PSCs in a dose-dependent manner. Although supernatants of untreated PSCs increased the proliferation, invasiveness, and migration of pancreatic cancer cells (PCC), supernatants of pirfenidone-treated PSCs decreased these effects. Exposure to PCC supernatant increased the production of platelet-derived growth factor-A, hepatic growth factor, collagen type I, fibronectin, and periostin in PSCs, which was significantly reduced by pirfenidone. Mice were subcutaneously implanted with PCCs (SUIT-2 cells) and PSCs into the right flank and PCCs alone into the left flank. Oral administration of pirfenidone to these mice significantly reduced tumor growth of co-implanted PCCs and PSCs, but not of PCCs alone. Pirfenidone also decreased the proliferation of PSCs and the deposition of collagen type I and periostin in tumors. In mice with orthotopic tumors consisting of PCCs co-implanted with PSCs, pirfenidone suppressed tumor growth, reduced the number of peritoneal disseminated nodules, and reduced the incidence of liver metastasis. Pirfenidone in combination with gemcitabine more effectively suppressed orthotopic tumor growth compared with pirfenidone or gemcitabine alone. In conclusion, our findings indicate that pirfenidone is a promising antitumor agent for pancreatic cancer, owing to its suppression of desmoplasia through regulating PSCs.",
author = "Shingo Kozono and Kenoki Ohuchida and Daiki Eguchi and Naoki Ikenaga and Kenji Fujiwara and Lin Cui and Kazuhiro Mizumoto and Masao Tanaka",
year = "2013",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-12-3180",
language = "English",
volume = "73",
pages = "2345--2356",
journal = "Cancer Research",
issn = "0008-5472",
number = "7",

}

TY - JOUR

T1 - Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells

AU - Kozono, Shingo

AU - Ohuchida, Kenoki

AU - Eguchi, Daiki

AU - Ikenaga, Naoki

AU - Fujiwara, Kenji

AU - Cui, Lin

AU - Mizumoto, Kazuhiro

AU - Tanaka, Masao

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Pancreatic stellate cells (PSC), which are implicated in desmoplasia in pancreatic cancer, enhance the malignancy of cancer cells and confer resistance to established treatments. We investigated whether the antifibrotic agent pirfenidone can suppress desmoplasia and exert antitumor effects against pancreatic cancer. Primary PSCs were established from pancreatic cancer tissue obtained during surgery. In vitro, pirfenidone inhibited the proliferation, invasiveness, and migration of PSCs in a dose-dependent manner. Although supernatants of untreated PSCs increased the proliferation, invasiveness, and migration of pancreatic cancer cells (PCC), supernatants of pirfenidone-treated PSCs decreased these effects. Exposure to PCC supernatant increased the production of platelet-derived growth factor-A, hepatic growth factor, collagen type I, fibronectin, and periostin in PSCs, which was significantly reduced by pirfenidone. Mice were subcutaneously implanted with PCCs (SUIT-2 cells) and PSCs into the right flank and PCCs alone into the left flank. Oral administration of pirfenidone to these mice significantly reduced tumor growth of co-implanted PCCs and PSCs, but not of PCCs alone. Pirfenidone also decreased the proliferation of PSCs and the deposition of collagen type I and periostin in tumors. In mice with orthotopic tumors consisting of PCCs co-implanted with PSCs, pirfenidone suppressed tumor growth, reduced the number of peritoneal disseminated nodules, and reduced the incidence of liver metastasis. Pirfenidone in combination with gemcitabine more effectively suppressed orthotopic tumor growth compared with pirfenidone or gemcitabine alone. In conclusion, our findings indicate that pirfenidone is a promising antitumor agent for pancreatic cancer, owing to its suppression of desmoplasia through regulating PSCs.

AB - Pancreatic stellate cells (PSC), which are implicated in desmoplasia in pancreatic cancer, enhance the malignancy of cancer cells and confer resistance to established treatments. We investigated whether the antifibrotic agent pirfenidone can suppress desmoplasia and exert antitumor effects against pancreatic cancer. Primary PSCs were established from pancreatic cancer tissue obtained during surgery. In vitro, pirfenidone inhibited the proliferation, invasiveness, and migration of PSCs in a dose-dependent manner. Although supernatants of untreated PSCs increased the proliferation, invasiveness, and migration of pancreatic cancer cells (PCC), supernatants of pirfenidone-treated PSCs decreased these effects. Exposure to PCC supernatant increased the production of platelet-derived growth factor-A, hepatic growth factor, collagen type I, fibronectin, and periostin in PSCs, which was significantly reduced by pirfenidone. Mice were subcutaneously implanted with PCCs (SUIT-2 cells) and PSCs into the right flank and PCCs alone into the left flank. Oral administration of pirfenidone to these mice significantly reduced tumor growth of co-implanted PCCs and PSCs, but not of PCCs alone. Pirfenidone also decreased the proliferation of PSCs and the deposition of collagen type I and periostin in tumors. In mice with orthotopic tumors consisting of PCCs co-implanted with PSCs, pirfenidone suppressed tumor growth, reduced the number of peritoneal disseminated nodules, and reduced the incidence of liver metastasis. Pirfenidone in combination with gemcitabine more effectively suppressed orthotopic tumor growth compared with pirfenidone or gemcitabine alone. In conclusion, our findings indicate that pirfenidone is a promising antitumor agent for pancreatic cancer, owing to its suppression of desmoplasia through regulating PSCs.

UR - http://www.scopus.com/inward/record.url?scp=84875992738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875992738&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-12-3180

DO - 10.1158/0008-5472.CAN-12-3180

M3 - Article

C2 - 23348422

AN - SCOPUS:84875992738

VL - 73

SP - 2345

EP - 2356

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 7

ER -